Lanja Saleh

Dr. Lanja Saleh


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2016 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
NBNoémie Boillat-Blanco
Noémie Boillat-Blanco
Pascal BovetPascal Bovet
Pascal Bovet
KRKaushik L. Ramaiya
Kaushik L. Ramaiya
MMMaliwasa Mganga
Maliwasa Mganga
LMLilian T. Minja
Lilian T. Minja
NPNicole Nicole Probst-Hensch
Nicole Nicole Probst-Hensch
Vitamin D level is inversely associated with tuberculosis (TB) and diabetes (DM). Vitamin D could be a mediator in the association between TB and DM. We examined the associations between vitamin D, TB and DM. Consecutive adults with TB and sex- and age-matched volunteers were included in a case-control study in Dar es Salaam, Tanzania. Glycemia and total vitamin D (25(OH)D) were measured at enrolment and after TB treatment in cases. The association between low 25(OH)D (<75 nmol/l) and TB was evaluated by logistic regression adjusted for age, sex, body mass index, socioeconomic status, sunshine hours, HIV and an interaction between low 25(OH)D and hyperglycemia. The prevalence of low 25(OH)D was similar in TB patients and controls (25.8 % versus 31.0 %; p = 0.22). In the subgroup of patients with persistent hyperglycemia (i.e. likely true diabetic patients), the proportion of patients with low 25(OH)D tended to be greater in TB patients (50 % versus 29.7 %; p = 0.20). The effect modification by persistent hyperglycemia persisted in the multivariate analysis (pinteraction = 0.01). Low 25(OH)D may increase TB risk in patients with underlying DM. Trials should examine if this association is causal and whether adjunct vitamin D therapy is beneficial in this population.

30 October 2022 in Advanced Science
Verified
Journal Article
Open access
GQGuangyu Qiu
Guangyu Qiu
MSMartin Spillmann
Martin Spillmann
JTJiukai Tang
Jiukai Tang
YZYi‐Bo Zhao
Yi‐Bo Zhao
YTYile Tao
Yile Tao
JWJing Wang
Jing Wang
On‐site quantification and early‐stage infection risk assessment of airborne severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) with high spatiotemporal resolution is a promising approach for mitigating the spread of coronavirus disease 2019 (COVID‐19) pandemic and informing life‐saving decisions. Here, a condensation (hygroscopic growth)‐assisted bioaerosol collection and plasmonic photothermal sensing (CAPS) system for on‐site quantitative risk analysis of SARS‐CoV‐2 virus‐laden aerosols is presented. The CAPS system provided rapid thermoplasmonic biosensing results after an aerosol‐to‐hydrosol sampling process in COVID‐19‐related environments including a hospital and a nursing home. The detection limit reached 0.25 copies/µL in the complex aerosol background without further purification. More importantly, the CAPS system enabled direct measurement of the SARS‐CoV‐2 virus exposures with high spatiotemporal resolution. Measurement and feedback of the results to healthcare workers and patients via a QR‐code are completed within two hours. Based on a dose‐responseµ model, it is used the plasmonic biosensing signal to calculate probabilities of SARS‐CoV‐2 infection risk and estimate maximum exposure durations to an acceptable risk threshold in different environmental settings.

1 January 2016 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
LSLanja Saleh
Lanja Saleh
DMDaniel Mueller
Daniel Mueller
AEArnold von Eckardstein
Arnold von Eckardstein
We evaluated the analytical and clinical performance of the new LumipulseTotal 25 hydroxy vitamin D (25(OH)D) levels were measured in 100 selected serum samples from our routine analysis with Fujirebio 25(OH)D assay. The results were compared with those obtained with LC-MS/MS and three other automated 25(OH)D assays (Abbott, Beckman, and Roche). The accuracy of each assay tested was evaluated against a Labquality reference serum panel for 25(OH)D (Ref!25OHD; University of Ghent).Intra- and inter-day imprecision of the Fujirebio 25(OH)D assay was <5%. Fujirebio 25(OH)D assay showed the highest correlation among the assays tested with the LC-MS/MS method (R=0.986). The mean relative bias obtained was –15.6% (Fujirebio), –12.7% (Beckman), –2.1% (Abbott) and 9.7% (Roche) as compared to LC-MS/MS. Comparison with the Labquality certified reference serum panel yielded a mean bias of –11.8% (Fujirebio), –14.1% (Beckman), 4.4% (Abbott) and 3.2% (Roche), respectively. Compared to LC-MS/MS, the sensitivity of different methods in detecting vitamin D insufficiency (<50 nmol/L) varied from 100% for the Fujirebio assay to 72.7% for Roche, and specificity ranged from 94.4% for Roche to 87.6% for Beckman.The Lumipulse

19 September 2017 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Closed access
PDF file
WAWijtske Annema
Wijtske Annema
ANAlbina Nowak
Albina Nowak
AEArnold von Eckardstein
Arnold von Eckardstein
LSLanja Saleh
Lanja Saleh

1 January 2016 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
VGViola Günther
Viola Günther
DMDaniel Mueller
Daniel Mueller
AEArnold von Eckardstein
Arnold von Eckardstein
LSLanja Saleh
Lanja Saleh
Background: Monitoring of plasma drug levels is mandatory in patients receiving high-dose methotrexate. This study evaluated the analytical performance of the novel Architect and the established ARK™ methotrexate immunoassay (running on the Roche CobasMethods: Imprecision and linearity were verified for the Architect and ARK assay according to CLSI EP15-A3 and EP6-A guidelines, respectively. The reported limit of quantitation (0.04 μmol/L) was tested for both assays according to the CLSI EP17-A2 guideline. Correlation and agreement between the different assays were evaluated using residual plasma samples (n=153).Results: Total imprecision was <6.3% and <9.5% for the Architect and ARK assay, respectively. The claimed linearity and limit of quantitation were confirmed for the Architect assay. For the ARK assay, imprecision at the limit of quantitation was <18% with a positive bias resulting in a high total error up to 58%, and hence the linearity could not be confirmed. Both assays showed strong correlations with the TDX assay and LC-MS but a positive bias of 12.2% and 20.5% in comparison to LC-MS for the Architect and ARK assay, respectively. For the ARK assay this bias increased dramatically for samples with concentrations towards the limit of quantitation.Conclusions: The Architect assay is suitable for monitoring plasma methotrexate, but the ARK assay showed unsatisfactory performance in the analysis of low concentrated samples. Unlike the TDX assay, both assays require manual dilution of samples at higher concentrations, which delays sample processing in clinical routine.

1 January 2017 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Open access
PDF file
LSLanja Saleh
Lanja Saleh
Jonathan TangJonathan Tang
Jonathan Tang
JGJoanna Gawinecka
Joanna Gawinecka
LBLukas Boesch
Lukas Boesch
WFWilliam D. Fraser
William D. Fraser
ANAlbina Nowak
Albina Nowak
Background: We investigate the effect of a high dose of vitamin D3 on circulating concentrations of 25(OH)D3 and its metabolites 24,25(OH)Methods: One hundred and seven study participants (age 20–50 years) were randomized to receive a single 100,000 IU dose of vitamin D3 (n=52) or placebo (n=55). Vitamin D metabolite concentrations in serum were measured before, and 4 weeks after, supplementation.Results: Overall, 52% of participants receiving vitamin D3 attained a serum 25(OH)D3 level >75 nmol/L. Among individuals who received vitamin D3, there were significant increases in serum concentrations of 25(OH)D3 and its metabolites 24,25(OH)Conclusions: Administration of a single high dose of vitamin D3 leads to a significant increase in concentrations of 25(OH)D3, 24,25(OH)